Streetbeat News

GUTS

Fractyl Health Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

2.14

Mkt cap

94M

Volume

380K

High

2.14

P/E Ratio

-1.43

52-wk high

14.50

Low

1.92

Div yield

N/A

52-wk low

1.74

Fractyl Health, Inc. (NASDAQ:GUTS) held its Q3 2024 earnings call, discussing financial results and business updates. Key participants included CEO Harith Rajagopalan and CFO Lisa Davidson.

Portfolio Pulse from

November 15, 2024 | 4:15 am

Fractyl Health, Inc. (Nasdaq: GUTS) reported its Q3 2024 financial results and provided updates on its weight maintenance and diabetes treatment studies. Key data releases are expected in late 2024 and mid-2025.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

Fractyl Health's stock is rising following the announcement that it will present new data on its Revita and Rejuva platforms at ObesityWeek 2024.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 12:28 pm

Fractyl Health is set to present data on weight maintenance from its Revita and Rejuva platforms at ObesityWeek 2024 on November 3 and 5. This presentation could provide insights into the effectiveness of their platforms in managing obesity.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 11:04 am

The article reports on the after-market session movements of various healthcare stocks. Notable gainers include Carmell (CTCX) with a 31% increase and Processa Pharma (PCSA) with a 30.07% rise. Among the losers, Soligenix (SNGX) saw an 8.6% decline, and Inspire Veterinary (IVP) fell by 6.34%.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 8:31 pm

Fractyl Health reported a net loss of $17.2 million for Q2. This financial result may impact investor sentiment and the stock price of the company.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:24 pm

Fractyl Health, Inc. (NASDAQ:GUTS) announced new clinical results from its German Real-World Registry, showing significant weight loss and blood sugar reduction in patients with obesity and Type 2 Diabetes after a single Revita endoscopic procedure. The results indicate a median weight loss of nearly 13% and a substantial decrease in HbA1c levels over 12 months.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:08 pm

Fractyl Health shares are trading higher after the company received FDA Device Designation for Revita, aimed at weight maintenance for people with obesity who discontinue GLP-1 based drugs.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:25 am

Fractyl Health has received FDA device designation for its Revita treatment, aimed at weight maintenance for people with obesity who discontinue GLP-1 based drugs.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:05 am

Fractyl Health, Inc. (NASDAQ:GUTS) is accelerating its REMAIN-1 clinical study and expanding the protocol for its REVITALIZE-1 study, potentially increasing the U.S. treatment population for its Revita device by nearly six-fold. The company aims to provide durable weight maintenance and enhanced glucose regulation for patients with obesity and type 2 diabetes (T2D). Key data from these studies are expected between Q4 2024 and mid-2025.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 10:07 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.